ACB vs. CRON, THCX, WEED, GUD, FIRE, OGI, EPI, CRDL, ICC, and CPH
Should you be buying Aurora Cannabis stock or one of its competitors? The main competitors of Aurora Cannabis include Cronos Group (CRON), Hydropothecary (THCX), Canopy Growth (WEED), Knight Therapeutics (GUD), Supreme Cannabis (FIRE), Organigram (OGI), ESSA Pharma (EPI), Cardiol Therapeutics (CRDL), ICC Labs (ICC), and Cipher Pharmaceuticals (CPH). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Aurora Cannabis (TSE:ACB) and Cronos Group (TSE:CRON) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and profitability.
9.0% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 15.9% of Cronos Group shares are owned by institutional investors. 46.5% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Aurora Cannabis has higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cronos Group had 1 more articles in the media than Aurora Cannabis. MarketBeat recorded 1 mentions for Cronos Group and 0 mentions for Aurora Cannabis. Cronos Group's average media sentiment score of 0.80 beat Aurora Cannabis' score of 0.80 indicating that Cronos Group is being referred to more favorably in the news media.
Aurora Cannabis received 459 more outperform votes than Cronos Group when rated by MarketBeat users. Likewise, 63.16% of users gave Aurora Cannabis an outperform vote while only 50.74% of users gave Cronos Group an outperform vote.
Aurora Cannabis has a beta of 2.65, meaning that its stock price is 165% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.
Aurora Cannabis presently has a consensus target price of C$2.26, suggesting a potential downside of 73.11%. Cronos Group has a consensus target price of C$3.18, suggesting a potential downside of 10.17%. Given Cronos Group's higher possible upside, analysts plainly believe Cronos Group is more favorable than Aurora Cannabis.
Aurora Cannabis has a net margin of 151.71% compared to Cronos Group's net margin of -61.31%. Cronos Group's return on equity of -4.99% beat Aurora Cannabis' return on equity.
Summary
Aurora Cannabis and Cronos Group tied by winning 9 of the 18 factors compared between the two stocks.
Get Aurora Cannabis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aurora Cannabis Competitors List
Related Companies and Tools
